CY1116304T1 - Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας - Google Patents
Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακαςInfo
- Publication number
- CY1116304T1 CY1116304T1 CY20151100243T CY151100243T CY1116304T1 CY 1116304 T1 CY1116304 T1 CY 1116304T1 CY 20151100243 T CY20151100243 T CY 20151100243T CY 151100243 T CY151100243 T CY 151100243T CY 1116304 T1 CY1116304 T1 CY 1116304T1
- Authority
- CY
- Cyprus
- Prior art keywords
- biotine
- therapeutic treatment
- treatment
- biotin
- relates
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 3
- 235000000638 D-biotin Nutrition 0.000 title 1
- 239000011665 D-biotin Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229960002685 biotin Drugs 0.000 abstract 1
- 235000020958 biotin Nutrition 0.000 abstract 1
- 239000011616 biotin Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1257254A FR2993780B1 (fr) | 2012-07-26 | 2012-07-26 | Methode de traitement de la sclerose en plaque |
| US13/644,615 US8835487B2 (en) | 2012-07-26 | 2012-10-04 | Method of treating multiple sclerosis |
| EP13719836.2A EP2729143B1 (en) | 2012-07-26 | 2013-04-29 | Use of biotin for the treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116304T1 true CY1116304T1 (el) | 2017-02-08 |
Family
ID=47294963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100243T CY1116304T1 (el) | 2012-07-26 | 2015-03-11 | Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8835487B2 (enExample) |
| EP (2) | EP2857019B1 (enExample) |
| JP (1) | JP6208235B2 (enExample) |
| KR (1) | KR101967502B1 (enExample) |
| CN (2) | CN104602689A (enExample) |
| AU (1) | AU2013295370B2 (enExample) |
| BR (1) | BR112015001562A2 (enExample) |
| CA (1) | CA2879434C (enExample) |
| CY (1) | CY1116304T1 (enExample) |
| DK (2) | DK2857019T3 (enExample) |
| EA (1) | EA030478B1 (enExample) |
| ES (3) | ES2811074T3 (enExample) |
| FR (1) | FR2993780B1 (enExample) |
| HK (1) | HK1207583A1 (enExample) |
| HR (1) | HRP20150260T1 (enExample) |
| HU (1) | HUE024558T2 (enExample) |
| IL (1) | IL236790A (enExample) |
| LT (1) | LT2857019T (enExample) |
| ME (1) | ME02060B (enExample) |
| PL (1) | PL2729143T3 (enExample) |
| PT (2) | PT2857019T (enExample) |
| RS (1) | RS53893B1 (enExample) |
| SI (2) | SI2729143T1 (enExample) |
| SM (1) | SMT201500057B (enExample) |
| WO (1) | WO2014016003A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) * | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| CA2910717C (en) | 2013-04-29 | 2021-01-26 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| EP3257881B1 (en) * | 2015-02-13 | 2020-09-02 | Unimatec Co., Ltd. | Fluorinated copolymer, and surface modifier containing same as active ingredient |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
| RU2638803C2 (ru) * | 2016-06-09 | 2017-12-15 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки биотина с замедленным высвобождением и способ их получения |
| RU2611415C1 (ru) * | 2015-11-17 | 2017-02-21 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты) |
| WO2017086835A1 (ru) * | 2015-11-17 | 2017-05-26 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты) |
| EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| CN109890384A (zh) | 2016-09-01 | 2019-06-14 | Jds治疗有限公司 | 生物素镁组合物和使用方法 |
| RU2639488C1 (ru) * | 2017-04-06 | 2017-12-21 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Фармацевтическая композиция, содержащая биотин, и способ ее получения |
| US20200155510A1 (en) * | 2018-11-13 | 2020-05-21 | Jds Therapeutics, Llc | Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions |
| CN112076310A (zh) * | 2019-06-14 | 2020-12-15 | 苏州融析生物科技有限公司 | 一种治疗多发性硬化的药物组合物及其制备 |
| IL294021A (en) | 2019-12-16 | 2022-08-01 | Nutrition 21 Llc | Methods of production of arginine-silicate complexes |
| PH12022551124A1 (en) | 2020-01-01 | 2023-08-23 | Celagenex Res India Pvt Ltd | Synergistic nutritional compositions for enhancing atp efficiency |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3609165A (en) | 1968-07-19 | 1971-09-28 | Research Corp | 1,3-diazabicyclo {8 3.1.0{9 {0 hex-3-enes |
| JPH0995448A (ja) | 1995-09-29 | 1997-04-08 | Calpis Food Ind Co Ltd:The | 血中ビオチン濃度の増加方法およびビオチン含有飲食品 |
| EP0891719A1 (en) * | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
| US5789401A (en) | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
| US6664039B1 (en) | 1998-10-14 | 2003-12-16 | California Institute Of Technology | Methods and compositions for modulating neurodegeneration |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| DE19903241A1 (de) | 1999-01-28 | 2000-08-03 | Merck Patent Gmbh | Galenische Formulierung |
| US20050256178A1 (en) | 2002-08-23 | 2005-11-17 | Eggersdorfer Manfred L | Novel nutraceutical compositions comprising boitin |
| US7709028B2 (en) | 2002-09-30 | 2010-05-04 | Daiichi Pharmaceutical Co., Ltd. | Particulate product comprising pantethine |
| DE10341240A1 (de) * | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| EP1706146B1 (en) * | 2003-12-31 | 2013-08-21 | K-Pax Pharmaceuticals, Inc. | Nutrient compositions and use thereof for enhanced effectiveness of the immune system |
| IL162288A0 (en) * | 2004-06-01 | 2005-11-20 | Future Products Man S A | Compositions and methods for treating neurodegenerative disorders |
| BG66011B1 (bg) * | 2005-05-25 | 2010-10-29 | Райна Щонова | Състав от растителен произход |
| BR112012015084A2 (pt) | 2009-12-23 | 2017-03-07 | Lupin Ltd | composição farmacêutica de liberação lenta de iloperidone |
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) * | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
-
2012
- 2012-07-26 FR FR1257254A patent/FR2993780B1/fr not_active Expired - Fee Related
- 2012-10-04 US US13/644,615 patent/US8835487B2/en active Active
-
2013
- 2013-04-29 PT PT141942136T patent/PT2857019T/pt unknown
- 2013-04-29 ES ES14194213T patent/ES2811074T3/es active Active
- 2013-04-29 PT PT13719836T patent/PT2729143E/pt unknown
- 2013-04-29 LT LTEP14194213.6T patent/LT2857019T/lt unknown
- 2013-04-29 RS RS20150168A patent/RS53893B1/sr unknown
- 2013-04-29 SI SI201330023T patent/SI2729143T1/sl unknown
- 2013-04-29 HK HK15108330.5A patent/HK1207583A1/xx unknown
- 2013-04-29 PL PL13719836T patent/PL2729143T3/pl unknown
- 2013-04-29 JP JP2015523453A patent/JP6208235B2/ja not_active Expired - Fee Related
- 2013-04-29 HR HRP20150260TT patent/HRP20150260T1/hr unknown
- 2013-04-29 ES ES13719836.2T patent/ES2532364T3/es active Active
- 2013-04-29 HU HUE13719836A patent/HUE024558T2/hu unknown
- 2013-04-29 BR BR112015001562A patent/BR112015001562A2/pt not_active Application Discontinuation
- 2013-04-29 EP EP14194213.6A patent/EP2857019B1/en active Active
- 2013-04-29 AU AU2013295370A patent/AU2013295370B2/en not_active Ceased
- 2013-04-29 KR KR1020157004516A patent/KR101967502B1/ko not_active Expired - Fee Related
- 2013-04-29 CN CN201380039687.3A patent/CN104602689A/zh active Pending
- 2013-04-29 WO PCT/EP2013/058936 patent/WO2014016003A1/en not_active Ceased
- 2013-04-29 ME MEP-2015-32A patent/ME02060B/me unknown
- 2013-04-29 SI SI201331768T patent/SI2857019T1/sl unknown
- 2013-04-29 EP EP13719836.2A patent/EP2729143B1/en active Active
- 2013-04-29 DK DK14194213.6T patent/DK2857019T3/da active
- 2013-04-29 DK DK13719836.2T patent/DK2729143T3/en active
- 2013-04-29 CN CN201910026016.2A patent/CN109908140A/zh active Pending
- 2013-04-29 CA CA2879434A patent/CA2879434C/en not_active Expired - Fee Related
- 2013-04-29 EA EA201590270A patent/EA030478B1/ru not_active IP Right Cessation
-
2014
- 2014-01-14 ES ES14700423.8T patent/ES2626079T3/es active Active
- 2014-08-13 US US14/458,625 patent/US9351961B2/en not_active Expired - Fee Related
-
2015
- 2015-01-19 IL IL236790A patent/IL236790A/en active IP Right Grant
- 2015-03-09 SM SM201500057T patent/SMT201500057B/xx unknown
- 2015-03-11 CY CY20151100243T patent/CY1116304T1/el unknown
-
2016
- 2016-04-12 US US15/096,957 patent/US10201528B2/en not_active Expired - Fee Related
-
2018
- 2018-12-21 US US16/231,111 patent/US20190117626A1/en not_active Abandoned
- 2018-12-21 US US16/231,073 patent/US20190117625A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1124740T1 (el) | Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης | |
| CY1122308T1 (el) | St2l ανταγωνιστες και μεθοδοι χρησης | |
| EA201590270A1 (ru) | Применение биотина для лечения рассеянного склероза | |
| CY1120646T1 (el) | Προγονικα κυτταρα μεσοδερμικης προελευσης | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| JO3343B1 (ar) | أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها | |
| MY172578A (en) | Oral dosing of glp-1 compounds | |
| DK3791896T5 (da) | Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling | |
| MX2020004986A (es) | Composiciones mejoradas para tratar distrofia muscular. | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| EP3604536C0 (en) | RNA MODULATING OLIGONUCLEOTIDES WITH ENHANCED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | |
| HRP20180939T1 (hr) | Kombinirana terapija za liječenje multiple skleroze | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
| UA117466C2 (uk) | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
| EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| PT2859896T (pt) | Composições farmacêuticas para o tratamento de distúrbios musculares | |
| UY34615A (es) | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
| CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης |